EU health policy
Freedom of choice for EU citizens
Some 100 million EU citizens make use of homeopathic and anthroposophic medicinal products. Today’s European citizens feel more responsible for their own health and treatment options. It is an important EU principle that patients should have access to the medicinal products of their choice, and this should include traditional medicinal products such as homeopathic and anthroposophic medicines, as much as it does innovative medicines.
Contribution to current EU priorities
Studies and data from the area of health insurance increasingly demonstrate the important economic benefit of integration of homeopathic and anthroposophic treatments in regular and standard healthcare. The products have an overall positive safety record, are available at low cost and can contribute to achieving key EU goals in the frame of health of the citizens.
Homeopathy and anthroposophic medicine and their related products have an important contribution to make to major EU health challenges and there are clear links with other Commission priorities, such as the current focus on resilient, accessible and sustainable health systems, chronic disease, healthy ageing, patient empowerment, and antimicrobial resistance.
Research in these fields confirms significant added values to society. These include:
- Comparative effectiveness
- Fewer side effects
- Comparative cost-effectiveness
- Sustainable health and satisfied patients.
Areas of EU health policy of importance for homeopathic and anthroposophic medicinal products
- Antimicrobial resistance
- Health inequalities
- Patient empowerment and patient-centredness
- Health in all policies
- Healthy and active ageing
- Chronic disease